Block its recycling system, and cancer kicks the can, according to new Penn studyMay 09, 2012
Potent new drug kills tumor cells in mice by clogging up their recycling system
PHILADELPHIA - All cells have the ability to recycle unwanted or damaged proteins and reuse the building blocks as food. But cancer cells have ramped up the system, called autophagy, and rely on it to escape damage in the face of chemotherapy and other treatments. Now, researchers at the Perelman School of Medicine; the Abramson Cancer Center; and the School of Arts and Sciences, at the University of Pennsylvania, have developed a potent new drug that clogs up the recycling machinery and kills tumor cells in mouse models.
Ravi K. Amaravadi, MD, assistant professor of Medicine, and colleagues showed previously that an old malaria drug, hydroxychloroquine, reduces autophagy in cancer cells and makes them more likely to die when exposed to chemotherapy. The strategy is currently being tested in clinical trials, and preliminary results are promising. The catch, though, is that it's not always possible to give patients a high enough dose of hydroxychloroquine to have an effect on their tumor cells.
Amaravadi teamed up with Jeffrey Winkler, PhD, the Merriam Professor of Chemistry, to design a series of more potent versions of chloroquine. They describe the design, chemical synthesis, and biological evaluation of a highly effective, new compound called Lys05, in the early edition of the Proceedings of the National Academy of Sciences this week.
Unlike hydroxychloroquine, which has little impact on tumor cells when used as a single agent, the new drug, called Lys05, slows tumor growth in animal models even in the absence of other anti-tumor therapies. What's more, the Lys05 dose that is toxic to cancer cells, which are addicted to recycling and rely on it much more heavily than healthy cells, has little or no effect on healthy cells.
"We see that Lys05 has anti-tumor activity at doses that are non-toxic for the animals," Amaravadi says. "This single-agent anti-tumor activity suggests this drug, or its derivative, may be even more effective in patients than hydroxychloroquine." Remarkably, however, when the investigators increase the dose of Lys05, some animals develop symptoms that mimic a known genetic deficiency in an autophagy gene, ATG16L1, which affects some patients with Crohn's disease . That similarity - technically called a phenocopy - clearly shows that Lys05 works by interfering with the recycling system in cells.
Lys05, and its companion compound Lys01, aren't quite ready for testing in patients, according to Amaravadi. Before that can happen, the molecules need to be optimized and undergo more toxicity testing in animals. Amaravadi and Winkler hope to team up with an industry partner for that portion of the project.
In the meantime, though, Amaravadi says the work illustrates just how important autophagy is to cancer cells, and provides an important new step for future therapies.
University of Pennsylvania School of Medicine
Related Hydroxychloroquine Current Events and Hydroxychloroquine News Articles
Researchers find promising treatment for devastating genetic disorder
A multi-institutional team of researchers has identified an apparently successful treatment for a genetic immune disorder that causes a multitude of health problems - ranging from infections, diabetes, lung disease and the body's immune system attacking and damaging healthy tissues.
Patients with primary hand OA should not be prescribed hydroxychloroquine
The results of an interventional trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that use of the disease-modifying anti-rheumatic drug hydroxychloroquine for 24 weeks did not diminish mild-moderate pain from primary hand osteoarthritis (OA).
Women with lupus and APS at risk of reduced fertility and pregnancy complication
New recommendations by EULAR for women's health and pregnancy in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) were presented today at the European League Against Rheumatism Annual Congress (EULAR 2015).
Patients grapple with high cost of arthritis medications
The first national investigation of Medicare coverage of biologic disease modifying drugs (DMARDs) found that in starting a single biologic DMARD, patients face more than $2,700 in copayments each year before receiving relief from catastrophic coverage.
In the quest for safer treatment for systemic lupus erythematosus
The treatment of systemic lupus erythematosus has traditionally been based on glucocorticoids administered orally.
Tamoxifen-resistant breast cancer reversed when drug paired with anti-malaria agent
The inexpensive anti-malarial drug hydroxychloroquine (HCQ) reverses resistance to tamoxifen, a widely used breast cancer drug, in mice.
Clinical trials designed to block autophagy in multiple cancers show promise
In the largest group of results to date, researchers from Penn Medicine's Abramson Cancer Center and other institutions have shown in clinical trials that the malaria drug hydroxychloroquine (HCQ) blocked autophagy in a host of aggressive cancers-glioblastoma, melanoma, lymphoma and myeloma, renal and colon cancers-and in some cases helped stabilize disease.
Long-term antibiotic treatment for Q fever causes weight gain
Scientists have unearthed still more evidence that antibiotics can contribute to obesity. Research published ahead of print in the journal Antimicrobial Agents and Chemotherapy suggests that patients on long-term antibiotic treatment gained weight and had significant changes in their gut microbiota.
Malaria drug combo could help prevent pregnancy complications in lupus patients
An anti-malaria drug combination might be useful in helping to prevent pregnancy complications in women with lupus and the related disorder antiphospholipid syndrome, Yale School of Medicine researchers have found in a new study published in the American Journal of Reproductive Immunology.
Mother's immunosuppressive medications not likely to put fetus at risk
Women with chronic autoimmune diseases who take immunosuppressive medications during their first trimester of pregnancy are not putting their babies at significantly increased risk of adverse outcomes, according to a Vanderbilt study released online by the journal Arthritis and Rheumatism.
More Hydroxychloroquine Current Events and Hydroxychloroquine News Articles